Mersana Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2016 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Mersana Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2016 to Q4 2024.
  • Mersana Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending December 31, 2024 was $694K, a 63.1% decline year-over-year.
  • Mersana Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $4.56M, a 43% decline year-over-year.
  • Mersana Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $4.56M, a 43% decline from 2023.
  • Mersana Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $8M.
  • Mersana Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$445K, a 63% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $4.56M $694K -$1.19M -63.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-03
Q3 2024 $5.75M $986K -$1.3M -56.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $7.05M $1.19M -$1.01M -45.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $8.06M $1.7M +$57K +3.48% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $8M $1.88M +$981K +109% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-03
Q3 2023 $7.02M $2.29M +$2.46M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $4.56M $2.19M +$2.66M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $1.9M $1.64M +$2.34M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$445K $902K +$1.85M Oct 1, 2022 Dec 31, 2022 10-K 2025-03-03
Q3 2022 -$2.3M -$172K -$89K -107% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$2.21M -$469K -$383K -445% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$1.83M -$706K -$625K -772% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$1.2M -$952K -$870K -1061% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$332K -$83K -$10K -13.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$322K -$86K -$88K -4400% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$234K -$81K -$299K -137% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $65K -$82K -$436K -123% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-26
Q3 2020 $501K -$73K -$574K -115% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $1.08M $2K -$683K -99.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $1.76M $218K -$234K -51.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $1.99M $354K +$5K +1.43% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 $1.99M $501K +$161K +47.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 $1.83M $685K +$336K +96.3% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 $1.49M $452K +$92K +25.6% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 $1.4M $349K -$34K -8.88% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $1.43M $340K +$22K +6.92% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-28
Q2 2018 $1.41M $349K +$191K +121% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-28
Q1 2018 $1.22M $360K +$309K +606% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-28
Q4 2017 $910K $383K +$336K +715% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-08
Q3 2017 $574K $318K +$264K +489% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-08
Q2 2017 $310K $158K +$142K +888% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-08
Q1 2017 $168K $51K +$47K +1175% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-08
Q4 2016 $121K $47K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-28
Q3 2016 $54K Jul 1, 2016 Sep 30, 2016 10-K 2018-03-28
Q2 2016 $16K Apr 1, 2016 Jun 30, 2016 10-K 2018-03-28
Q1 2016 $4K Jan 1, 2016 Mar 31, 2016 10-K 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.